Detailed Individual SUSAR/CIOMS Report

Dear TACL T2017-002 Ixazomib Study Investigator:

As investigators participating in a clinical trial using the investigational medicinal product (IMP) ixazomib, PPD Global has issued the following safety reports below.  The details of these adverse events/safety issues are being reported in compliance with regulations.

What The Investigator Needs To Do With This Information:

• Evaluate the adverse events associated with the use of Nivolumab for reporting to your local IRB, and if required, submit it within the required timeframe